12,372 trials
COVID-19
Primary: Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29 — 10.0; 15.5 days — p=0.6672
Recurrent Glioblastoma
Primary: Percentage of Participants With Drug-Related Adverse Events Leading to Discontinuation by Worst CTC Grade for All Treated Participants in Cohorts 1, 1b, 1c and 1d Who…
Non-small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Independent Review Committee (IRC) — 7.0; 11.1…
Fabry Disease
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03 — 21; 19; 4; 4 participants
Pulmonary Surgical Procedures
Primary: Predicted Percentage of Remaining Pulmonary Function — 73.4; 71.9 percentage of remaining function
COVID-19
Primary: The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical…
Anemia · Dialysis-Dependent Chronic Kidney Disease
Primary: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) — 0.19; 0.36 Grams per deciliter (g/dL)
Hemophagocytic Lymphohistiocytosis
Primary: Number of Participants With Adverse Event (AE) — 37; 12; 7 Participants
Influenza
Primary: Time From First Dose to Symptom Response — 155.1; 153.9 hours — p=0.3765
Pulmonary Disease, Chronic Obstructive
Primary: Response in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 - 12 Hours (AUC0-12) — 0.187; 0.117; 0.057; 0.211 Liter (L) — p=<0.0001
Gastric Cancer · Gastroesophageal Junction Cancer · Esophageal Adenocarcinoma
Primary: Overall Survival (OS) in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy With PD-L1 CPS ≥ 5 — 14.39; 11.10 Months — p=<0.0001
Spondyloarthritis
Primary: Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response in Biological Disease-modifying Antirheumatic Drug…
Asthma
Primary: Patients Who Achieve 100% Reduction in Daily OCS Dose — 376 Participants
Anemia · Non-Dialysis-Dependent Chronic Kidney Disease
Primary: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) — 1.43; 1.38 g/dL
Anemia · Non-Dialysis-Dependent Chronic Kidney Disease
Primary: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) — 0.41; 0.42 Grams per deciliter (g/dL)